CV6-1271 is a novel small molecule therapeutic that is designed to work with standard-of-care therapies in inflammatory conditions such as rheumatoid arthritis. Inflammatory conditions are caused by abnormal immune cell behaviour leading to the immune system improperly infiltrating and attacking normal cells and tissues. This abnormal immune cell behaviour leads to inflammation that can result in chronic pain, redness, swelling, stiffness, and damage to normal tissues depending on the condition. CV6 Therapeutics is developing innovative new medicines that will work in combination with standard treatments to better control the behaviour of these damaging immune cells, alleviate symptoms and improve patient quality of life.
Our first small molecule therapeutic for inflammatory conditions, CV6-1271, is in pre-clinical development.